The Neurobiology of Bipolar Disorder.
Bipolar disorder
Hormones
Inflammation
Neurobiology
Neuroendocrine
Neurotrophins
Oxidadtive stress
Journal
Current topics in behavioral neurosciences
ISSN: 1866-3370
Titre abrégé: Curr Top Behav Neurosci
Pays: Germany
ID NLM: 101535383
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
15
1
2021
medline:
1
4
2021
entrez:
14
1
2021
Statut:
ppublish
Résumé
Bipolar disorders are severe and have a high prevalence; despite this, the neurobiological mechanisms are far from being elucidated, and this limits the development of new treatments. Although the aetiology of bipolar disorders is not yet fully understood, it is accepted that the disorder(s) may result from the interaction between genetic factors that cause susceptibility and predisposing, precipitating and perpetuating environmental factors, such as stress and traumatic events. A pathophysiological formulation of the disease suggests that dysfunctions in intracellular biochemical cascades, oxidative stress and mitochondrial dysfunction impair the processes linked to neuronal plasticity, leading to cell damage and the consequent loss of brain tissue that has been identified in post-mortem and neuroimaging studies. The data we have reviewed suggests that peripheral biomarkers related to hormones, inflammation, oxidative stress and neurotrophins are altered in bipolar disorders, especially during acute mood episodes. Together, these changes have been associated with a systemic toxicity of the disease and the damage resulting from multiple episodes. Systemic toxicity related to recurrent episodes in bipolar disorder may influence brain anatomical changes associated with the progression of stress and neuroplasticity in bipolar disorder and the response to treatment.
Identifiants
pubmed: 33442840
doi: 10.1007/7854_2020_179
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-20Références
Ackenheil M (2001) Neurotransmitters and signal transduction processes in bipolar affective disorders: a synopsis. J Affect Disord 62(1–2):101–111
pubmed: 11172877
Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, Callegari MG, Sandonà D, Markwardt F, Schmalzing G, Di Virgilio F (2010) Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 24(9):3393–3404
pubmed: 20453110
Altamura C, Mauri M, Ferrara A, Moro A, D'Andrea G, Zamberlan F (1993) Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150:1731–1733
pubmed: 8214185
Anand A, Barkay G, Dzemidzic M, Albrecht D, Karne H, Zheng QH, Hutchins GD, Normandin MD, Yoder KK (2011) Striatal dopamine transporter availability in unmedicated bipolar disorder. Bipolar Disord 13(4):406–413
pubmed: 21843280
Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 111(2-3):135–144
pubmed: 18539338
Bäckström P, Hyytiä P (2003) Attenuation of cocaine-seeking behaviour by the AMPA/kainate receptor antagonist CNQX in rats. Psychopharmacology (Berl) 166:69–76
Barnett JH, Smoller JW (2009) The genetics of bipolar disorder. Neuroscience 164(1):331–343
pubmed: 19358880
pmcid: 3637882
Baumann B, Danos P, Krell D, Diekmann S, Wurthmann C, Bielau H et al (1999) Unipolar-bipolar dichotomy of mood disorders is supported by noradrenergic brainstem system morphology. J Affect Disord 54(1–2):217–224
pubmed: 10403168
Beaulieu JM, Gainetdinov RR (2011) The physiology, signalling, and pharmacology of dopamine receptors. Pharmacol Rev 63(1):182–217
pubmed: 21303898
Belvederi Murri M, Prestia D, Mondelli V et al (2016) The HPA axis in bipolar disorder: systematic review and metaanalysis. Psychoneuroendocrinology 63:327–342
pubmed: 26547798
Beneyto M, Meador-Woodruff J (2006) Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse 60:585–598
pubmed: 16983646
Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, Norman T (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 434:41–49
Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PV, Amminger P, McGorry P, Malhi GS (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35(3):804–817
pubmed: 20934453
Berk M, Berk L, Dodd S, Cotton S, Macneil C, Daglas R, Conus P, Bechdolf A, Moylan S, Malhi GS (2014) Stage managing bipolar disorder. Bipolar Disord 16(5):471–477
pubmed: 23782499
Bhagwagar Z et al (2008) Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 11(2):255–260
pubmed: 17625025
Bobo WV (2017) The diagnosis and management of bipolar I and II disorders: clinical practice update. Mayo Clin Proc 92(10):1532–1551
pubmed: 28888714
Bonan CD (2012) Ectonucleotidases and nucleotide/nucleoside transporters as pharmacological targets for neurological disorders. CNS Neurol Disord Drug Targets 11(6):739–750
pubmed: 22963442
Bosaipo NB, Borges VF, Juruena MF (2017) Bipolar disorder: a review of conceptual and clinical aspects. Medicina 50(Suppl 1):72–84
Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC (2006) Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112(2):358–404
pubmed: 16784779
Brady RO et al (2013) Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord 15(4):434–439
pubmed: 23634979
pmcid: 5504910
Brown NC, Andreazza AC, Young LT (2014) An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 218(1–2):61–68
pubmed: 24794031
Brundege JM, Dunwiddie TV (1997) Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv Pharmacol 39:353–391
pubmed: 9160120
Brunello N, Tascedda F (2003) Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol 6(2):181–189
pubmed: 12890311
Bunney WE Jr, Garland BL (1982) A second generation catecholamine hypothesis. Pharmacopsychiatria 15(4):111–115
pubmed: 6292964
Burnstock G, Verkhratsky A (2010) Long-term (trophic) purinergic signalling: Purinoceptors control cell proliferation, differentiation and death. Cell Death Dis 1:e9
pubmed: 21364628
pmcid: 3032501
Caspi A, Moffitt TE (2006) Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 7(7):583–590
pubmed: 16791147
Cataldo AM, McPhie DL, Lange NT, Punzell S, Elmiligy S, Ye NZ et al (2010) Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am J Pathol 177(2):575–585
pubmed: 20566748
pmcid: 2913344
Clinton SM, Meador-Woodruff JH (2004) Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 29:1353–1362
pubmed: 15054476
Colino A, García-Seoane JJ, Valentín A (1998) Action potential broadening induced by lithium may cause a presynaptic enhancement of excitatory synaptic transmission in neonatal rat hippocampus. Eur J Neurosci 10:2433–2443
pubmed: 9749771
Cuthbert BN, Insel TR (2013) Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med 11:126
pubmed: 23672542
pmcid: 3653747
de Kloet ER, Joëls M (2017) Brain mineralocorticoid receptor function in control of salt balance and stress-adaptation. Physiol Behav 178:13–20
pubmed: 28089704
de Oliveira GS, Ceresér KM, Fernandes BS et al (2009) Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 43:1171–1174
pubmed: 19473667
Derijk RH, van Leeuwen N, Klok MD, Zitman FG (2008) Corticosteroid receptor-gene variants: modulators of the stress-response and implications for mental health. Eur J Pharmacol 585(2–3):492–501
pubmed: 18423443
Di Virgilio F, Ceruti S, Bramanti P, Abbracchio MP (2009) Purinergic signalling in inflammation of the central nervous system. Trends Neurosci 32(2):79–87
pubmed: 19135728
Dong XX, Wang Y, Qin ZH (2009) Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 30:379–387
pubmed: 19343058
pmcid: 4002277
Du J, Gray NA, Falke C, Yuan P, Szabo S, Manji HK (2003) Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann N Y Acad Sci 1003:378–380
pubmed: 14684466
Du F, Yuksel C, Chouinard VA, Huynh P, Ryan K, Cohen BM, Öngür D (2018) Abnormalities in high-energy phosphate metabolism in first-episode bipolar disorder measured using 31P-magnetic resonance spectroscopy. Biol Psychiatry 84(11):797–802
pubmed: 28527566
Duchen MR (2000) Mitochondria and Ca(2+)in cell physiology and pathophysiology. Cell Calcium 28(5–6):339–348
pubmed: 11115373
Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59(12):1116–1127
pubmed: 16631126
Ellenbogen MA, Santo JB, Linnen AM, Walker CD, Hodgins S (2010) High cortisol levels in the offspring of parents with bipolar disorder during two weeks of daily sampling. Bipolar Disord 12:77–86
pubmed: 20148869
Fam SR, Gallagher CJ, Salter MW (2000) P2Y(1) purinoceptor-mediated Ca(2+) signaling and Ca(2+) wave propagation in dorsal spinal cord astrocytes. J Neurosci 20(8):2800–2808
pubmed: 10751431
pmcid: 6772222
Fee C, Banasr M, Sibille E (2017) Somatostatin-positive GABA Interneuron deficits in depression: cortical microcircuit and therapeutic perspectives. Biol Psychiatry 82(8):549–559
pubmed: 28697889
pmcid: 5610074
Gebhardt C, Cull-Candy SG (2010) Lithium acts as a potentiator of AMPAR currents in hippocampal CA1 cells by selectively increasing channel open probability. J Physiol 588:3933–3941
pubmed: 20807790
pmcid: 3000583
Gomez-Sanchez E, Gomez-Sanchez CE (2014) The multifaceted mineralocorticoid receptor. Compr Physiol 4(3):965–994
pubmed: 24944027
pmcid: 4521600
Hahn CG, Friedman E (1999) Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord 1(2):81–86
pubmed: 11252663
Harris AP, Holmes MC, de Kloet ER, Chapman KE, Seckl JR (2013) Mineralocorticoid and glucocorticoid receptor balance in control of HPA axis and behaviour. Psychoneuroendocrinology 38(5):648–658
pubmed: 22980941
Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64(4):341–357
pubmed: 20653908
Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310–1316
pubmed: 17574216
Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F (2000) Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 25(5):513–518
pubmed: 10818284
Hoekstra R, Fekkes D, Loonen A, Pepplinkhuizen L, Tuinier S, Verhoeven W (2006) Bipolar mania and plasma amino acids: increased levels of glycine. Eur Neuropsychopharmacol 16:71–77
pubmed: 16023835
Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24:677–736. Review
pubmed: 11520916
pmcid: 2758233
Joyce PR, Fegursson DM, Woollard G, Abbott RM, Horwood LJ, Upton J (1995) Urinary catecholamines and plasma hormones predict mood state in rapid cycling bipolar affective disorder. J Affect Disord 33(4):233–243
pubmed: 7790677
Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM (2010) The prednisolone suppression test in depression: dose-response and changes with antidepressant treatment. Psychoneuroendocrinology 35(10):1486–1491
pubmed: 20558006
pmcid: 3513406
Juruena MF (2014) Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav 38:148–159
pubmed: 24269030
Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ (2009) Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry 194:342–349
pubmed: 19336786
Juruena MF, Baes CW, Menezes IC, Graeff FG (2015) Early life stress in depressive patients: role of glucocorticoid and mineralocorticoid receptors and of hypothalamic-pituitary-adrenal axis activity. Curr Pharm Des 21(11):1369–1378
pubmed: 25564387
Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM et al (2017) HPA Axis in major depression: cortisol, clinical symptomatology, and genetic variation predict cognition. Mol Psychiatry 22(4):527–536
pubmed: 27528460
Kristiansen L, Meador-Woodruff J (2005) Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 78:87–93
pubmed: 16023328
Kurita M, Nishino S, Numata Y, Okubo Y, Sato T (2014) The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study. PLoS One 9(6):e100634
pubmed: 24971450
pmcid: 4074114
Law AJ, Deakin JF (2001) Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12:2971–2974
pubmed: 11588613
Leach MJ, Marden CM, Miller AA (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27:490–497
pubmed: 3757936
Lemmens R, Vanduffel L, Teuchy H, Culic O (1996) Regulation of proliferation of LLC-MK2 cells by nucleosides and nucleotides: the role of ectoenzymes. Biochem J 316(Pt 2):551–557
pubmed: 8687400
pmcid: 1217384
Lin PY (2009) State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 466:139–143
pubmed: 19786073
Luján R, Shigemoto R, López-Bendito G (2005) Glutamate and GABA receptor signalling in the developing brain. Neuroscience 130:567–580
pubmed: 15590141
Luscher B, Shen Q, Sahir N (2011) The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 16(4):383–406
pubmed: 21079608
Machado-Vieira R, Dietrich MO, Leke R et al (2007) Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 61:142–144
pubmed: 16893527
Machado-Vieira R, Manji HK, Zarate CA Jr (2009) The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 11(Suppl 2):92–109
pubmed: 19538689
pmcid: 2800957
Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN (2007) Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry 41:321–326
pubmed: 17464718
Manji HK, Henter ID, Zarate CA Jr (2011) Bipolar disorder: a neurobiological synthesis. Curr Top Behav Neurosci 5:331–340
pubmed: 25236563
pmcid: 4292837
Maripuu M, Wikgren M, Karling P, Adolfsson R, Norrback KF (2016) Relative hypocortisolism is associated with obesity and the metabolic syndrome in recurrent affective disorders. J Affect Disord 204:187–196
pubmed: 27367307
Mazer AK, Cleare AJ, Young AH, Juruena MF (2019) Bipolar affective disorder and borderline personality disorder: differentiation based on the history of early life stress and psychoneuroendocrine measures. Behav Brain Res 357–358:48–56
pubmed: 29702176
McCullumsmith R, Kristiansen L, Beneyto M, Scarr E, Dean B, Meador-Woodruff J (2007) Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127:108–118
pubmed: 17113057
McEwen B (2006) Dialogues Clin Neurosci 8(4)
Monteleone P, Serritella C, Martiadis V, Maj M (2008) Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 10:95–100
pubmed: 18199246
Moylan S, Maes M, Wray N, Berk M (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 18:595–606
pubmed: 22525486
Murck H, Schüssler P, Steiger A (2012) Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. Pharmacopsychiatry 45(3):83–95
pubmed: 22290200
Murck H, Braunisch MC, Konrad C, Jezova D, Kircher T (2019) Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression. Int Clin Psychopharmacol 34(1):18–26
pubmed: 30300165
Obata T (2002) Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm (Vienna) 109(9):1159–1180
Palomino A, Vallejo-Illarramendi A, González-Pinto A et al (2006) Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 86:321–322
pubmed: 16829047
Petty F, Kramer GL, Fulton M, Moeller FG, Rush AJ (1993) Low plasma GABA is a marker of a characteristic similar to bipolar disorder. Neuropsychopharmacology 9(2):125–132
pubmed: 8216695
Post RM (2007) Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 41(12):979–990
pubmed: 17239400
Prange AJ Jr, Wilson IC, Lynn CW, Alltop LB, Stikeleather RA (1974) L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 30(1):56–62
pubmed: 4587067
Rahn KA, Slusher BS, Kaplin AI (2012) Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr Med Chem 19:1335–1345
pubmed: 22304712
Rao J, Ertley R, Rapoport S, Bazinet R, Lee H (2007) Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. J Neurochem 102:1918–1927
pubmed: 17550430
Ribeiro JA, Sebastiao AM, de Mendonca A (2003) Participation of adenosine receptors in neuroprotection. Drug News Perspect 16(2):80–86
pubmed: 12792668
Sanacora G et al (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61(7):705–713
pubmed: 15237082
Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH (2007) Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61:822–825
pubmed: 17141740
Sanacora G, Zarate CA, Krystal JH, Manji HK (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426–437
pubmed: 2715836
pmcid: 2715836
Sanz JM, Di Virgilio F (2000) Kinetics and mechanism of ATP-dependent IL-1 beta release from microglial cells. J Immunol 164(9):4893–4898
pubmed: 10779799
Scaini G, Rezin GT, Carvalho AF, Streck EL, Berk M, Quevedo J (2016) Mitochondrial dysfunction in bipolar disorder: evidence, pathophysiology and translational implications. Neurosci Biobehav Rev 68:694–713
pubmed: 27377693
Scaini G, Fries GR, Valvassori SS, Zeni CP, Zunta-Soares G, Berk M et al (2017) Perturbations in the apoptotic pathway and mitochondrial network dynamics in peripheral blood mononuclear cells from bipolar disorder patients. Transl Psychiatry 7(5):e1111
pubmed: 28463235
pmcid: 5534951
Scola G, Andreazza AC (2015) The role of neurotrophins in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 56:122–128
pubmed: 25193130
Shiah IS, Yatham LN (2000) Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord 2(2):77–92
pubmed: 11252655
Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J (2010) Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res 35(9):1295–1301
pubmed: 20499165
van Leeuwen N, Bellingrath S, de Kloet ER, Zitman FG, DeRijk RH, Kudielka BM, Wüst S (2011) Human mineralocorticoid receptor (MR) gene haplotypes modulate MR expression and transactivation: implication for the stress response. Psychoneuroendocrinology 36(5):699–709
pubmed: 21095064
Wang JF, Shao L, Sun X, Young LT (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11:523–529
pubmed: 19624391
Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH (2004) Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 184:496–502
pubmed: 15172943
Wilkinson ST, Sanacora G (2019) A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems. Drug Discov Today 24(2):606–615
pubmed: 30447328
Yoshimura R, Nakano Y, Hori A et al (2006) Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol 21:433–438
pubmed: 17029305
Young LT, Warsh JJ, Kish SJ et al (1994) Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry 35:121–127
pubmed: 7513191
Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57(4):430–432
pubmed: 15705360
Zarate CJ, Singh J, Manji H (2006) Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 59:1006–1020
pubmed: 16487491